AU2012380583B2 - Pharmaceutical composition for the prophylaxis and treatment of psychological, behavioral and cognitive disorders - Google Patents

Pharmaceutical composition for the prophylaxis and treatment of psychological, behavioral and cognitive disorders Download PDF

Info

Publication number
AU2012380583B2
AU2012380583B2 AU2012380583A AU2012380583A AU2012380583B2 AU 2012380583 B2 AU2012380583 B2 AU 2012380583B2 AU 2012380583 A AU2012380583 A AU 2012380583A AU 2012380583 A AU2012380583 A AU 2012380583A AU 2012380583 B2 AU2012380583 B2 AU 2012380583B2
Authority
AU
Australia
Prior art keywords
melatonin
memantine
pharmaceutical composition
composition according
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Revoked
Application number
AU2012380583A
Other languages
English (en)
Other versions
AU2012380583A1 (en
Inventor
Allan Gerovich Beniashvili
Margarita Alekseevna MOROZOVA
Maxim Eduardovich ZAPOLSKY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Valenta Intellect LLC
Original Assignee
Valenta Intellect LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Valenta Intellect LLC filed Critical Valenta Intellect LLC
Publication of AU2012380583A1 publication Critical patent/AU2012380583A1/en
Application granted granted Critical
Publication of AU2012380583B2 publication Critical patent/AU2012380583B2/en
Revoked legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2012380583A 2012-05-24 2012-10-31 Pharmaceutical composition for the prophylaxis and treatment of psychological, behavioral and cognitive disorders Revoked AU2012380583B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
RU2012121410 2012-05-24
RU2012121410/15A RU2488388C1 (ru) 2012-05-24 2012-05-24 Фармацевтическая композиция для профилактики и лечения психических, поведенческих, когнитивных расстройств
PCT/RU2012/000888 WO2013176567A1 (ru) 2012-05-24 2012-10-31 Фармацевтическая композиция для профилактики и лечения психических, поведенческих, когнитивных расстройств

Publications (2)

Publication Number Publication Date
AU2012380583A1 AU2012380583A1 (en) 2014-12-18
AU2012380583B2 true AU2012380583B2 (en) 2015-01-22

Family

ID=49155569

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012380583A Revoked AU2012380583B2 (en) 2012-05-24 2012-10-31 Pharmaceutical composition for the prophylaxis and treatment of psychological, behavioral and cognitive disorders

Country Status (14)

Country Link
US (1) US20150157604A1 (enExample)
EP (1) EP2857011A4 (enExample)
JP (1) JP5864819B2 (enExample)
KR (1) KR101581611B1 (enExample)
CN (1) CN104334166A (enExample)
AU (1) AU2012380583B2 (enExample)
CA (1) CA2873891C (enExample)
EA (1) EA201400973A1 (enExample)
HK (1) HK1205467A1 (enExample)
IL (1) IL235852A0 (enExample)
IN (1) IN2014DN09940A (enExample)
RU (1) RU2488388C1 (enExample)
UA (1) UA112352C2 (enExample)
WO (1) WO2013176567A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2536270C1 (ru) * 2013-10-21 2014-12-20 Общество с ограниченной ответственностью ООО "ВАЛЕНТА ИНТЕЛЛЕКТ" Комбинация для коррекции неврологического и психоэмоционального статуса при органических нарушениях цнс
ES2943587T3 (es) 2015-11-24 2023-06-14 Massachusetts Inst Technology Sistemas para prevenir, atenuar y/o tratar demencia
WO2018004391A1 (ru) * 2016-06-29 2018-01-04 Общество С Ограниченной Ответственностью "Валента-Интеллект" Фармацевтическая композиция, содержащая комбинацию мемантина и мелатонина
RU2623865C1 (ru) * 2016-06-29 2017-06-29 Общество С Ограниченной Ответственностью "Валента-Интеллект" Фармацевтическая композиция, содержащая комбинацию мемантина и мелатонина
RU2654713C1 (ru) * 2016-06-29 2018-05-22 Общество С Ограниченной Ответственностью "Валента-Интеллект" Фармацевтическая композиция, содержащая комбинацию мемантина и мелатонина
US10849856B2 (en) 2016-10-31 2020-12-01 Neurim Pharmaceuticals Ltd. Melatonin mini-tablets and method of manufacturing the same
DK3337462T3 (da) 2016-10-31 2020-10-12 Neurim Pharma 1991 Melatonin-minitabletter og fremgangsmåde til fremstilling heraf
KR102612531B1 (ko) 2016-11-17 2023-12-12 코그니토 쎄라퓨틱스, 인코포레이티드 인지 기능 개선을 위한 시스템
ES3058718T3 (en) 2017-10-10 2026-03-12 Massachusetts Inst Technology Systems for preventing, mitigating, and/or treating dementia
US10960225B2 (en) 2017-10-10 2021-03-30 Massachusetts Institute Of Technology Systems and methods for preventing, mitigating, and/or treating dementia via visual stimulation that binds higher order brain regions, reduces neurodegeneration and neuroinflammation, and improves cognitive function

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6034134A (en) * 1997-06-30 2000-03-07 Merz + Co. Gmbh & Co. 1-Amino-alkylcyclohexane NMDA receptor antagonists

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES413944A1 (es) 1972-04-20 1976-06-01 Merz & Co Procedimiento para la preparacion de compuestos de adamen- tano trisustituidos en las posiciones 1,3,5.
DE2856393C2 (de) 1978-12-27 1983-04-28 Merz + Co GmbH & Co, 6000 Frankfurt Arzneimittel zur Behandlung von Morbus Parkinson
DE58905637D1 (de) 1989-04-14 1993-10-21 Merz & Co Gmbh & Co Verwendung von Adamantan-Derivaten zur Prävention und Behandlung der cerebralen Ischämie.
US5614560A (en) 1991-04-04 1997-03-25 Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
US6469044B1 (en) 1995-02-01 2002-10-22 Neurim Pharmaceuticals (1991) Ltd. Method for treating patients suffering from drug dependencies which lead to plasma melationin deficiencies
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
US20050129783A1 (en) * 2001-04-19 2005-06-16 Mccleary Edward L. Composition and method for treatment of neurophysiological conditions and maintenance of neurophysiological health
US7183321B2 (en) * 2001-12-17 2007-02-27 Bristol-Myers Squibb Company Antidiabetic formulation and method
CN101897736A (zh) 2002-10-30 2010-12-01 Asat应用科学技术股份公司 含有褪黑素、银杏和生物素的制剂
RU2268737C2 (ru) 2004-02-16 2006-01-27 Государственное учреждение институт клинической иммунологии СО РАМН Способ лечения атопического дерматита
US8039009B2 (en) * 2004-06-17 2011-10-18 Forest Laboratories Holdings Limited Modified release formulations of memantine oral dosage forms
EP1841460A2 (en) * 2004-06-18 2007-10-10 Neurochem (International) Limited Therapeutic formulations for the treatment of beta-amyloid related diseases
AU2005286672B2 (en) * 2004-09-23 2009-03-12 Merz Pharma Gmbh & Co. Kgaa Memantine for the treatment of childhood behavioral disorders
MY148806A (en) * 2005-04-04 2013-05-31 Takeda Pharmaceutical Prophylactic or therapeutic agent for nocturnal conduct disorder associated with dementia
CN1709230A (zh) * 2005-07-05 2005-12-21 北京阜康仁生物制药科技有限公司 盐酸美金刚分散片及其制备方法
RU2294741C1 (ru) 2005-08-08 2007-03-10 Рина Михайловна Заславская Способ лечения больных ишемической болезнью сердца, стабильной стенокардией в сочетании с артериальной гипертонией
KR20090024140A (ko) * 2006-05-22 2009-03-06 반다 파마슈티칼즈, 인코퍼레이티드. 우울증 질환에 대한 치료
AU2007253684A1 (en) * 2006-05-22 2007-11-29 Vanda Pharmaceuticals, Inc. Treatment for depressive disorders
EP1886670A1 (en) * 2006-07-05 2008-02-13 Teva Pharmaceutical Industries Ltd Pharmaceutical compositions of memantine
WO2008005534A2 (en) * 2006-07-06 2008-01-10 Forest Laboratories, Inc. Orally dissolving formulations of memantine
GB0623897D0 (en) * 2006-11-30 2007-01-10 Pliva Istrazivanje I Razvoj D Pharmaceutical composition of memantine
WO2008083204A2 (en) * 2006-12-28 2008-07-10 Braincells, Inc. Modulation of neurogenesis by melatoninergic ligands
RU2326660C1 (ru) 2007-03-14 2008-06-20 Закрытое акционерное общество "Биологические исследования и системы" Пероральный лекарственный препарат мемантин (варианты) и способ его получения (варианты)
JP5600058B2 (ja) 2007-04-11 2014-10-01 ファーマシューティカル プロダクションズ， インコーポレイテッド メラトニンタブレットならびに調剤及び使用方法
US8728532B2 (en) 2007-04-12 2014-05-20 Regents Of The University Of Minnesota Ischemia/reperfusion protection compositions and methods of using
US20100256184A1 (en) * 2008-08-13 2010-10-07 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
WO2010089132A1 (en) * 2009-02-06 2010-08-12 Egalet A/S Immediate release composition resistant to abuse by intake of alcohol
RU2394571C1 (ru) 2009-05-14 2010-07-20 Государственное бюджетное учреждение здравоохранения города Москвы "Городская клиническая больница № 24" Департамента здравоохранения города Москвы Способ лечения воспалительных заболеваний кишечника
RU2418586C2 (ru) 2009-06-11 2011-05-20 Государственное образовательное учреждение высшего профессионального образования "Новосибирский государственный медицинский университет Федерального агентства по здравоохранению и социальному развитию" (ГОУ ВПО НГМУ Росздрава) Способ коррекции нарушений в репродуктивных органах, вызванных высокой температурой
RU2428183C1 (ru) 2010-07-01 2011-09-10 Рина Михайловна Заславская Адаптоген для метеочувствительных больных стенокардией и артериальной гипертензией и применение мелатонина в качестве адаптогена

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6034134A (en) * 1997-06-30 2000-03-07 Merz + Co. Gmbh & Co. 1-Amino-alkylcyclohexane NMDA receptor antagonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
A Reiter RJ et al. Medical implications of melatonin: receptor-mediated and receptor-independent actions. Advances in Medical Sciences, 2007; 52:11-28 *

Also Published As

Publication number Publication date
HK1205467A1 (en) 2015-12-18
RU2488388C1 (ru) 2013-07-27
EA201400973A1 (ru) 2015-02-27
JP2015517569A (ja) 2015-06-22
IN2014DN09940A (enExample) 2015-08-14
WO2013176567A1 (ru) 2013-11-28
JP5864819B2 (ja) 2016-02-17
KR101581611B1 (ko) 2015-12-31
CN104334166A (zh) 2015-02-04
US20150157604A1 (en) 2015-06-11
KR20150005999A (ko) 2015-01-15
IL235852A0 (en) 2015-01-29
EP2857011A4 (en) 2015-12-02
CA2873891C (en) 2016-02-16
EP2857011A1 (en) 2015-04-08
UA112352C2 (uk) 2016-08-25
CA2873891A1 (en) 2013-11-28
AU2012380583A1 (en) 2014-12-18

Similar Documents

Publication Publication Date Title
AU2012380583B2 (en) Pharmaceutical composition for the prophylaxis and treatment of psychological, behavioral and cognitive disorders
US11116773B2 (en) Method of treating dementia
US20220096491A1 (en) Compositions and methods for treating alzheimer's disease and parkinson's disease
EP3443987B1 (en) A pharmaceutical composition for prevention of diet induced obesity
KR20150048888A (ko) 항콜린 신경보호 조성물 및 그 방법
US12138269B2 (en) Method of treating dementia
CN115776885A (zh) 用于治疗阿尔茨海默病和帕金森病的组合物和方法
EP3962488A1 (en) A method of treating mental, behavioral, cognitive disorders
US20250152544A1 (en) Sleep-improving compositions and methods of use
US20260014098A1 (en) Fenchol as a stimulator of free fatty acid receptor and other uses thereof
WO2015060746A1 (ru) Комбинация для лечения и/или профилактики проявлений психических, когнитивных, поведенческих и неврологических нарушений при органических заболеваниях цнс различного генеза
US9999614B2 (en) Combination for the prophylaxis and treatment of behavioural, mental, and cognitive disorders
CN121370879A (zh) 治疗边缘型人格障碍的方法
CN107441105A (zh) 人参二醇皂苷Rb组分在制备防治疼痛药物中的应用
CN111939139A (zh) 一种盐酸美金刚缓释和盐酸多奈哌齐速释胶囊及其制备方法
KR20240070564A (ko) 알츠하이머병 예방 또는 치료용 약학적 조성물
KR20250052203A (ko) 방사선 뇌인지/행동 장애의 예방 또는 치료를 위한 2-메톡시에스트라디올을 포함하는 약학 조성물
KR20220160269A (ko) 갈라민트리에티오디드를 유효성분으로 포함하는 근육질환의 예방 또는 치료용 약학적 조성물
KR20220107597A (ko) 인지 장애 예방 또는 개선용 조성물
CA3223922A1 (en) Medicaments comprising glycosidase inhibitors

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MAK Offer to surrender letters patent
MAL Surrender and revocation of letters patent

Effective date: 20160922